Why Zevra Therapeutics Is On Investor Radar Today
Zevra Therapeutics (ZVRA) has drawn investor attention after recent trading, with the share price closing at US$9.23 and posting mixed short term returns alongside stronger total returns over the past 3 years.
See our latest analysis for Zevra Therapeutics.
The recent 7 day share price return of 7.51% and 1 day decline of 1.81% come after a period of steadier momentum. The 30 day share price return of 3.82% and the 3 year total shareholder return of 68.74% suggest that longer term holders have seen stronger gains than recent traders.
If Zevra has you thinking about where else growth or rerating potential might be hiding, this could be a good moment to scan for 35 healthcare AI stocks.
With Zevra trading at US$9.23 against an analyst price target of US$22.78 and an estimated intrinsic discount of 87%, investors have to ask: is this a genuine entry point, or is the market already pricing in future growth?
Most Popular Narrative: 65.7% Undervalued
Talos values Zevra at $26.89 per share versus the last close at $9.23, framing the stock as a rare disease commercial story rather than a speculative bet.
Zevra Therapeutics is at the most profitable inflection point in biotechnology, the transition from cash-burning R&D to cash-generating commercial sales. With the recent FDA approval of Miplyffa (for Niemann-Pick disease type C), Zevra has secured the first and only approved treatment for this ultra-rare condition.
Want to see what supports that higher fair value? The narrative leans on fast revenue expansion, rising margins and a richer earnings multiple than today. The exact assumptions might surprise you.
Result: Fair Value of $26.89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on rare disease demand and successful Phase 3 outcomes; weaker uptake or trial setbacks could quickly challenge the rerating story.
Find out about the key risks to this Zevra Therapeutics narrative.
Next Steps
Mixed signals so far, right? If this balance of risk and reward has your attention, now is a good time to review the 5 key rewards and 1 important warning sign
Looking for more investment ideas?
If Zevra has sparked your interest, do not stop here; broaden your watchlist with focused ideas that could sharpen your next investing move.
- Target resilient balance sheets and steady fundamentals by reviewing the solid balance sheet and fundamentals stocks screener (39 results).
- Hunt for strong businesses that the market may be overlooking with the screener containing 26 high quality undiscovered gems.
- Zero in on companies offering meaningful income potential by checking out the 13 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com